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132 Poster Session IIIL-2/GM-CSF except for mild flu-like symptoms. The table below
summarizes quantitative analysis of immune activation. Values rep-
resent means1/- standard error at day 0 (first day of GM-CSF), day
8 (prior to start of IL-2) and day 14 (last day of IL-2 and GM-CSF).
P-values are based on paired t-test analysis of day 8 versus day 0 and
day 14 versus day 0, respectively. Flow cytometric analysis showed
an increase in the numbers of T-lymphocytes (CD3) andT-cell sub-
sets (CD3/CD8 and CD3/CD4) as well as an increase in natural
killer cells (CD16/56). Although no differences were seen in the
number of dendritic cell subsets, DC1/DC2 ratios decreased with
the administration of GM-CSF/IL-2. Limited (n 5 4) CD4/
FoxP3 analysis did not show change in absolute numbers with
administration of GM-CSF/IL-2 (data not shown). In conclusion,
cytokine therapy with IL-2/GM-CSF is well tolerated and is an
alternative to DLI for relapse after ASCT. Flow cytometry analysis
demonstrated a quantitative increase in immune effector cells and
polarization to DC2.Flow Cytometry of Immune Effector Cells
D0 D8 D14 P-Value P-Value(Mean ± SE) (Mean ± SE) (Mean ± SE) (Day 8–0) (Day 14–0)CD3 (K/uL) 309 ± 117 535 ± 103 1306 ± 403 0.034 0.027CD3/CD8 (K/uL) 94 ± 42 174 ± 33 325 ± 90 0.021 0.029CD3/CD4 (K/uL) 309 ± 117 404 ± 102 977 ± 310 0.249 0.045CD16/CD56 (K/uL) 124 ± 60 404 ± 110 496 ± 162 0.029 0.044CD19 (K/uL) 68 ± 39 89 ± 36 116 ± 31 0.183 0.044Tot. Lymphs (K/uL) 488 ± 167 942 ± 160 2353 ± 532 0.016 0.013CD11(DC1) (K/uL) 97 ± 60 46 ± 32 33 ± 27 0.108 0.101CD123(DC2) (K/uL) 32 ± 7 40 ± 16 45 ± 36 0.694 0.628DC1/DC2 2.77 ± 1.26 0.68 ± 0.35 0.61 ± 0.07SE 5 Standard Error; DC5 dendritic cells.360
WHERE TO BIOPSY IN THE GASTROINTESTINAL (GI) TRACT TO DIAG-
NOSE ACUTE GRAFT VERSUS HOST DISEASE (AGVHD) IN PEDIATRIC
ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS (AlloSCT)
Martinez, M., Billote, G., Desai, M., Chu, K., Remotti, H., Satwani, P.,
Cairo, M.S., DeFelice, A. Columbia University, New York, NY.
Background & Aims: Despite therapeutic advances, GI
AGVHD continues to be a serious threat after alloSCT contribut-
ing to significant morbidity and mortality (Yacoub-Agha, et al,
Transplantation 2004). GI endoscopy, although critical to estab-
lishing early diagnosis and grading of AGVHD, poses additional
risks such as bleeding and perforation to already immunocompro-
mised patients. The objective of this study was to determine if upper
GI endoscopy (ED) with duodenum biopsy (Bx) adds diagnostic ac-
curacy to lowerGI ED and colon biopsy in pediatric alloSCT recip-
ients. Methods: We performed a retrospective review of pediatric
alloSCT recipients who underwent upper (UE) and lower (LE)
GI ED at Morgan Stanley Children’s Hospital-New York Presby-
terian between 2001 and 2005. Biopsies were evaluated by a gastro-
intestinal pathologist blinded to clinical data to correlate biopsy
sites with histological findings of GI AGVHD. To examine which
sites were more likely to be diagnostic of AGVHD, six pairwise
comparisons were made between different sites, using the McNe-
mar Test with Bonferroni correction so that p\ 0.008 (50.05/6)
represents statistical significance. Results: We evaluated 50 pa-
tients (age range 0.8 to 17.6 yr, mean 7.6 yr; M 27, F 23) 24 to
100 days post alloSCT suspected of AGVHD who underwent
both upper and lower GI ED. The number of Bx sites per patient
ranged from 4 to 10, median 7. For upper endoscopy, 48 patients
had both duodenal and stomach biopsies, the duodenum was
more likely to be positive than stomach, OR 3.7 (p 5 0.005). For
lower endoscopy cases, there were no significant differences in pro-
portion of positive biopsies between ascending and sigmoid, sig-
moid and transverse, or left versus right colon. However,
comparing LE to UE, left colon was significantly more likely to
be positive than duodenum, OR 12.0 (p 5 0.006). There were 12
cases where the left colon was positive and duodenum negative
and only 1 case where the reverse was true. Conclusions: Overall,duodenum and colon are most likely sites to be positive for GI
AGVHD. Left-sided colonoscopy and left colon biopsy are more
sensitive to detect AGVHD compared to upper endoscopy and gas-
tric and duodenal biopsies. Eliminating concomitant upper endos-
copy and biopsies if a lower endoscopy is performed could
potentially reduce morbidity in pediatric allograft recipients. How-
ever, if upper endoscopy is indicated, duodenal biopsies yield amore
accurate diagnosis than gastric biopsies.361
THE PHARMACODYNAMIC ANALYSIS BETWEEN CYCLOSPORINE A (CsA)
AND CYTOKINE PROFILES OF CD41 T LYMPHOCYTES FOR THE DEVEL-
OPMENT OF OPTIMIZED IMMUNOSUPPRESSIVE THERAPY WITH CsA
AFTER UNRELATED CORD BLOOD TRANSPLANTATION (CBT)
Tsukada, N.1, Ishige, M.2, Konuma, T.1, Kato, S.1, Kasahara, S.1,
Tomonari, A.1, Ooi, J.1, Tojo, A.1, Watanabe, N.2, Nakauchi, H.2,
Masuko, M.3, Furukawa, T.3, Aizawa, Y.3, Takahashi, S.1. 1 Institute
of Medical Science, University of Tokyo, Minato Ward, Tokyo, Japan;
2 Institute of Medical Science, University of Tokyo, Minato Ward, Tokyo,
Japan; 3Niigata University Medical and Dental Hospital, Niigata City,
Niigata, Japan.
Although unrelated cord blood transplantation (CBT) is increas-
ing in number, the optimized immunosuppressive therapy for pre-
vention of graft versus host disease (GVHD) has not been
established. Cyclosporine A (CsA) is the most common immuno-
suppressant used for GVHD prophylaxis and individualization
among types of stem cell source by using therapeutic drug monitor-
ing (TDM) is essential to optimize pharmacotherapy. Cord blood
lymphocytes are naı¨ve and most of CBT are carried out with a hu-
man leukocyte antigen (HLA)-mismatched combination especially
in adults. Our retrospective analysis showedCsA can be tapered ear-
lier for recipients of CBT than for those of BMT. To optimize CsA
administration in CBT, we analyzed proportion of IL-2 producing
cells among CD41T lymphocytes using multi-color flow cytomet-
ric analysis before and after CsA administration. We analyzed 55
peripheral blood samples from 6 allogeneic BMT recipients as con-
trols and 104 peripheral blood samples from 7 CBT recipients.
Cells were cultured in the presence of phorbol 12-myristate 13-ac-
etate, ionomycin, and monensin at 37C for 4 hrs and then stained
for surface markers and intracytoplasmic IL-2. Blood CsA levels
were simultaneouslymeasured.We found that the level of IL-2 pro-
duction in CD41 T lymphocytes was inversely proportional to
blood CsA levels for both BMT and CBT. IL-2 production in
CD41 T lymphocytes of cord blood recipients can be inhibited
by relatively lower CsA concentration compared with that of bone
marrow recipients. To our most interest, there was dramatic differ-
ence in required blood CsA level for inhibition of IL-2 production
by days after transplantation (e.g. before and after day45) in recipi-
ents of CBT, while there was no difference by days after transplan-
tation in recipients of BMT. This finding can explain why earlier
tapering of CsA is possible for cord blood recipients. Further anal-
ysis is needed to optimize blood CsA level on different days after
CBT for GVHD prophylaxis.362
INCIDENCE AND RISK FACTORS FOR CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD) AFTER CORD BLOOD TRANSPLANTATION (CBT)
Saliba, R.M.1, Couriel, D.2, Komanduri, K.1, Patah, P.3, Westin, J.1,
Giralt, S.1, Cooper, L.4, Petropoulos, D.4, Worth, L.4, Safdar, A.5,
Champlin, R.E.1, Shpall, E.J.1, de Lima, M.1. 1UTMDAnderson Can-
cer Center, Houston, TX; 2Tennesse Oncology, Nashville, TN; 3Hospital
Sirio Libanes, Sao Paulo, Brazil; 4UT MD Anderson Cancer Center,
Houston, TX; 5UT MD Anderson Cancer Center, Houston, TX.
Objective:To evaluate the impact of patient and transplant char-
acteristics on the incidence of cGVHD after CBT.Methods: Ret-
rospective study of all CBT performed at our institution between
1996 and 2007, excluding primary graft failure cases. 114 patients
were analyzed. All had high-risk hematologic malignancies; 59%
were in complete remission or chronic phase at transplantation.
Median age was 37 years (range 18–67) in the adult group (n 5
61) and 7 years (range 0.5–17) in the pediatric group (n 5 53).
Poster Session II 133Conditioning regimen was myeloablative for 92% of patients. It in-
cluded TBI in 39%, and ATG in 55%. GVHD prophylaxis was ta-
crolimus-based (except for 2 patients) with methotrexate (75%) or
MMF (19%). 44 patients (39%) received double CB units and 70
(61%) single units. Units were ex-vivo expanded for 20/44 and 9/
70 patients, respectively. Median number of infused total nucleated
cells (TNC) was 3.5 107/kg (1–7) and 4.7 107/kg (0.6–56) in the
adult and pediatric groups, respectively. cGVHD was defined ac-
cording to the recent NIH consensus criteria. Risk factors were
evaluated byCox’s regression analysis including age, gender, disease
status at transplantation, a prior autologous transplant, condition-
ing regimen, use of ATG in conditioning, GVHD prophylaxis,
number of CB units received, number of infused TNC, HLA-A,
B, or DRB1 mismatch, and early withdrawal of immunosuppres-
sion.Results:With amedian followupof 9months, 21/114 patients
developed cGVHD at a median of 126 days post CBT (range 100–
276). 62% of these cases (n 5 13) were de Novo. Recipient age
was the strongest risk factor with a significantly higher 1-year cumu-
lative incidence in adult patients (31%) compared with pediatric pa-
tients (n 5 4, 8%), p 5 0.002), despite a comparable incidence of
grade II-IV (38% and 34%) and III-IV (14% and 10%) acute
GVHD; and a superior disease free survival in the pediatric group.
In adult patients, a prior autologous transplant (n 5 16) was the
only significant risk factor, and was associated with a higher inci-
dence (50%versus 23%, p50.02). cGVHDwas extensive in thema-
jority of adult cases (12/17), yet it was associated with a lower rate of
relapse (HR 5 0.1, p 5 0.07) and mortality (HR 5 0.4, p 5 0.06)
when evaluated as time dependent variable in a landmark analysis
startingonpost SCTday1100.Conclusions:Recipient age is a sig-
nificant predictor of cGVHD following CBT. In adult patients, the
impact of prior autologous transplant deserves further evaluation.363
EARLY DETECTION OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE
USING PLASMA MARKERS OF T-CELL ACTIVATION
August, K.J.1, Chiang, K.-Y.1, Bostick, R.M.2, Waller, E.K.3,
Langston, A.3, Khoury, H.J.3, Moore, K.F.4, Worthington-White, D.1,
Rowland, P.1, Horan, J.T.1. 1Emory University, Atlanta, GA; 2Rollins
School of Public Health, Emory University, Atlanta, GA; 3Winship Can-
cer Institute, Emory University School of Medicine, Atlanta, GA; 4Emory
University School of Medicine, Atlanta, GA.
Severe acute graft-versus-host disease (GVHD) is a significant
cause of transplant related mortality in patients that receive alloge-
neic hematopoietic stem cell transplantation (HSCT). Treatment
of grade III and IV GVHD is frequently ineffective. Preemptive
treatment based on the early detection of cytokines associated
with T-cell activation and subclinical GVHD might be a more ef-
fective strategy, similar to the monitoring of CMV infection after
HSCT.
Various plasma markers of T cell activation, soluble IL-2 recep-
tor (sIL-2R) in particular, have been shown to correlate with cellular
immune responses in several diseases, including GVHD. Building
on this work, as the first step toward developing an early treatment
approach for severe GVHD, we conducted a prospective, observa-
tional study evaluating three plasma markers of T-cell activation.
sIL-2R, sCD40L and sCD8 were evaluated as screening tests with
the goal of detecting GVHD in its incipient stages prior to clinical
manifestations.
Wemeasured plasma levels of these markers on days 5 and 10 fol-
lowing HSCT. Testing was performed in 50 transplants (49 pa-
tients). The median age of patients was 14 (range: 0–67); 19
received genotypically matched related transplants, 4 received mis-
matched related transplants, 20 received unrelated transplants, and
7 received unrelated cord blood transplants. This population in-
cluded patients with both malignant and non-malignant diseases
and who received myeloablative and reduced intensity conditioning
regimens. Nine patients developed grade III or IV GVHD. Re-
ceiver operating curves were generated for each of the markers at
both time points. This analysis showed sIL-2R and sCD8 to be
more accurate markers than sCD40L. Day 10 levels correlated
more closely with outcome than those measured on day 5. A parallel
testing strategy combining sIL-2R and sCD8 yielded results supe-
rior to using either marker alone.An elevation of sIL2r above 20 ng/mL or sCD8 above 4400 units/
mL on day 10 was seen in 8 out of 9 patients that developed grade III
or IVGVHD yielding a sensitivity of 0.89. For the specificity calcu-
lation, patients with grade II GVHD were considered to be cases,
since these patients routinely receive systemic treatment. This
method produced a specificity of 0.57.
The results of this pilot study demonstrate the feasibility of using
biomarkers of T-cell activation for the early detection of severe
acute GVHD. Plans are underway for a larger, more definitive ob-
servational study.364
THE RELATIONSHIP BETWEEN TACROLIMUS SERUM CONCENTRATIONS
AND ACUTE GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC STEM CELL
RECIPIENTS
Trifilio, S.M., Flickner, S., Sheldon, S., Pi, J., Evens, A., Frankfurt, O.,
Gordon, L., Singhal, S., Tallman, M., Williams, S., Winter, J.,
Mehta, J. Northwestern University, Chicago, IL.
Tacrolimus is commonly used as prophylaxis of GVHD follow-
ing allogeneic HSCT. While there is an association between in-
creasing serum tacrolimus levels and the incidence of renal
toxicity, there is no established relationship between tacrolimus
levels and the incidence of GVHD. We studied the outcome of
92 consecutive allogeneic blood HSCT recipients receiving tacroli-
mus-based GVHD prophylaxis. 55 had received conventional-in-
tensity conditioning (usually busulfan-fludarabine; 34 unrelated
donors and 21 sibling donors) where tacrolimus was combined
with short-course methotrexate, and 36 had received reduced-in-
tensity conditioning (melphalan6 cyclophosphamide; all unrelated
donors) where tacrolimus was combined withmycophenolatemofe-
til. For each patient, a weekly average tacrolimus level was deter-
mined for each of the first 7 weeks post-transplant by averaging
all the levels available for that week. The relationship between the
average weekly tacrolimus levels and the occurrence of any grade
of acute GVHDwas examined. The ANOVA test was used to com-
pare the weekly average tacrolimus levels between patients who de-
veloped GVHD and those who did not. The cumulative incidence
of acute GVHD was compared by tacrolimus level categories each
week. A total of 1385 tacrolimus levels were available (6–45 per pa-
tient; median 14). The cumulative incidence of acute GVHD at 60
days was 37% (95%CI: 29–49%). As the table below shows, the av-
erage tacrolimus levels amongst patients going on to develop acute
GVHDtended to be lower than those not developing acuteGVHD;
significantly so for week 4 and showing a trend towards significnace
for weeks 5 and 6. The cumulative incidence of acute GVHD
amongst patients whose week 3 average tacrolimus was\10 was
51% (95% CI: 39–68%) compared with 24% (95% CI: 14–41%)
for those with a level of$10 (P5 0.015). Similarly, the cumulative
incidence of acute GVHD amongst patients whose week 4 average
tacrolimus was\10 was 43% (95% CI: 32–59%) compared with
20% (95% CI: 10–41%) for those with a level of $10 (P 5
0.046). The relationship between higher acute GVHD incidence
and lower tacrolimus levels was observed for other weeks and tacro-
limus cut-off levels, but the differences were not statistically signif-
icant. Our data suggest that there is a relationship between
tacrolimus levels and acute GVHD. How this affects relapse rates,
transplant-relatedmortality, and survival remains to be determined.Median average tacrolimus levels in patients with or without acute
GVHD
Week Acute GVHD No acute GVHD P1 13.6 13.1 0.97
2 11.1 12.1 0.21
3 8.9 10.9 0.20
4 7.3 8.5 0.031
5 8.6 10.2 0.057
6 7.8 9.1 0.06
7 7.5 8.1 0.25
